KRAS G12D Inhibitor Reshapes Immune Landscape, Enhances NK Cell Therapy

◇ RESEARCH

Preclinical research shows that KRAS G12D inhibition with MRTX1133 remodels the tumor immune environment by reducing immunosuppressive cells and facilitating infiltration of natural killer and CD8+ T cells, reversing systemic immunosuppression and restoring fitness of adoptively transferred NK cells. (Science Advances)